BioPharma Credit PLC USD · LSE:BPCP
BioPharma Credit PLC USD — BioPharma Credit — Investor Presentation (September 2022)
25 slides from BioPharma Credit PLC USD's investor presentation, September 2022
Slide 1: Debt Capital for the Life Sciences Industry
Debt Capital for the Life Sciences Industry COMPANY PRESENTATION – September 2022 For additional information please email: ir@bpcruk.com or visit BioPharma Credit’s website at www.bpcruk.com
Slide 2: Disclaimer
Disclaimer THIS PRESENTATION IS BEING PROVIDED TO YOU SOLELY FOR YOUR INFORMATION. THIS PRESENTATION IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR WITHIN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTI
Slide 3: Disclaimer
Disclaimer This presentation was prepared using the financial information available to the Company as at the date of this presentation. Except where otherwise indicated herein, the information provided in this presentation is based on matters as they exist as of the date of preparation and not as of
Slide 4: Experienced Investment Team
Experienced Investment Team Pedro Gonzalez de Cosio Martin Friedman Pablo Legorreta Co-Founder, Principal and CEO Principal Co-Founder and Principal Co-founded Pharmakon in 2009 Joined Pharmakon in 2011 Co-Founded Pharmakon in 2009 after 17 years in structured after 18 years in healthcare Foun
Slide 5: Investment Opportunity – Summary
Investment Opportunity – Summary The Life Sciences Debt Market is an Underserved, Large and Growing Opportunity Worldwide $1.1tn industry growing at 6% per annum Large capital needs, private companies spent $180bn in R&D during 2018¹ Industry dynamics create new debt investment opportunities
Slide 6: BPCR has generated consistent returns since IPO
BPCR has generated consistent returns since IPO1 BPCR annualized2 dividends per share in US$ Interim dividend has consistently met the annualized $0.070 target for almost four years 2017 2018 2019 2020 2021 2022 Price and NAV TR performance3 since IPO A consistent dividend has led to a steady in
Slide 7: Investment track record of mostly singles and doubles
Investment track record of mostly singles and doubles – Emphasis on consistency and reduced risk 97% of past Pharmakon transactions have generated returns > 10% (30 Realized Transactions)1 27% (8) > 15.0% 70% (21) 10.0% > <15.0% 3% (1) < 10.0% 1. Realized Internal Rate of Return to the Funds (Gross
Slide 8: The right structure / LTV helps generate attractive returns on debt irrespective of equity performance
The right structure / LTV helps generate attractive returns on debt irrespective of equity performance Life Sciences Debt Investments are less risky and are exposed to less volatility than the corresponding equity investments ■ The chart below shows the cash on cash returns of all past Pharmakon inv
Slide 9: New investments have allowed BPCR to broaden its diversification
New investments have allowed BPCR to broaden its diversification and deploy cash from capital raises and loan repayments Evolution of BPCR Portfolio since IPO1 (US$m) Seed Assets $339 Other realized $1,344 Total invested by Debt as of BPCR since IPO $2,778 30 June 2022 $138 Amortizations $65 Total r
Slide 10: BPCR currently has ~$1.4bn invested across transactions
BPCR currently has ~$1.4bn invested across 10 transactions ($ millions) BPCR % of Total Assets IRR to Investment Ticker Total Amount Share (%) Share ($) Maturity1 Bristol Myers BMY $122.9 High single % 100% $122.9 Optinose OPTN $130.0 11.8% 55% $71.5 Akebia AKBA $100.0 10.8% 50% $50.0 Global Blood G
Slide 11: Life Sciences is a $1 Trillion + Vital Industry with Sales that are Uncorrelated
Life Sciences is a $1 Trillion + Vital Industry with Sales that are Uncorrelated and Unaffected by Economic Cycles Global Pharmaceutical Sales: Historical & Projected ($, Trn) R/D/Innovation Create Growth Drivers 4 Large New Markets 1 Growing Population Known Existing Diseases: Treatments: 2 Ageing
Slide 12: Life Sciences is a $1 Trillion + Vital Industry (cont'd)
Life Sciences is a $1 Trillion + Vital Industry with Sales that are Uncorrelated and Unaffected by Economic Cycles (cont’d) Annual Changes in Sales of Oncology Drugs vs Major Indices 100% $140 Oncology Sales $Bn Oncology Sales (% change) Barclays US HY Index (% change) 80% $120 SP500 Index (% change
Slide 13: Small and midsize companies are involved in a majority of newly approved drugs
Small and midsize companies (target borrowers) are involved in a majority of newly approved drugs Drug Approvals by Size of Drug Originator Source: Bloomberg, Pharmakon Advisors 12
Slide 14: The life sciences industry has benefited from healthy capital inflows
The life sciences industry has benefited from healthy capital inflows, even in uncertain markets 13 Source: Bloomberg (includes all priced transactions that are categorized as biotechnology, pharmaceuticals, or medical devices)
Slide 15: BPCR's portfolio is primarily composed of senior secured loans to listed companies
BPCR’s portfolio is primarily composed of senior secured loans to listed companies Investment: Investment Date: November 1, 2017 September 12, 2019 November 25, 2019 December 20, 2019 February 13, 2020 Upsize Date: December 14, 2021 March 22, 2022 Structure: Royalty Stream Secured Loan Secured Loan
Slide 16: $650m senior secured loan to finance Collegium's acquisition of BDSI
$650m senior secured loan to finance Collegium’s acquisition of BDSI Collegium Pharmaceutical: biopharmaceutical company focused on developing and commercializing new medicines for responsible pain management. Market Cap: $608m as of August 19 2022 Cash: $123m as of June 30 2022 LTM 2Q22 PF
Slide 17: $100m senior secured corporate loan
$100m senior secured corporate loan UroGen: Biopharmaceutical company focused on developing products to treat specialty cancers and urologic diseases. The Company’s products are being developed as chemoablation agents designed to remove tumors by non-surgical means. The Company is focused on treat
Slide 18: $300m senior secured corporate loan
$300m senior secured corporate loan1 Coherus BioSciences: Biopharmaceutical company building a leading immuno-oncology franchise funded with cash generated by its commercial biosimilars business Market Cap: $983m as of August 19 2022 Cash: $276m as of June 30 2022 LTM Sales: $276m as of June
Slide 19: $125m senior secured corporate loan
$125m senior secured corporate loan Evolus: Biopharmaceutical company with a customer-centric approach focused on delivering breakthrough performance beauty products Market Cap: $573m as of August 19 2022 Cash: $85m as of June 30 2022 LTM Sales: $132m as of June 30 2022 Main Product: Jeuve
Slide 20: $300m senior secured corporate loan
$300m senior secured corporate loan LumiraDx: A next-generation point-of-care (POC) diagnostic company addressing the current limitations of legacy POC systems by bringing lab- comparable performance in minutes on a single instrument for a broad menu of tests with a low cost of ownership. Market
Slide 21: $550m senior secured corporate loan
$550m senior secured corporate loan Sarepta Therapeutics: Biopharmaceutical company focused on therapies for neuromuscular diseases Market Cap: $9,445m as of August 19 2022 Cash: $1,928m as of June 30 2022 LTM Sales: $746m as of June 30 2022 Main products: v EXONDYS 51 (eterplirsen) approv
Slide 22: $250m senior secured corporate loan
$250m senior secured corporate loan Global Blood Therapeutics: Biopharmaceutical company focused on developing and marketing therapies for sickle cell disease Market Cap: $4,521m as of August 19 2022 Cash: $666m as of June 30 2022 LTM Sales: $235m as of June 30 2022 Main Product: Oxbryta®
Slide 23: $100m senior secured corporate loan
$100m senior secured corporate loan Akebia Therapeutics is a biopharmaceutical company focused on the development and commercialization of therapeutic for patients with kidney disease. Market Cap: $70m as of August 19 2022 Cash: $144m as of June 30 2022 LTM Sales: $164m as of June 30 2022
Slide 24: $130m senior secured corporate loan
$130m senior secured corporate loan Optinose: Specialty pharmaceutical company focused on products for patients treated by ear, nose, and throat (ENT) and allergy specialists. Market Cap: $291m as of August 19 2022 Cash: $78m as of June 30 2022 LTM Sales: $80m as of June 30 2022 Main produ
Slide 25: Funds managed by Pharmakon Advisors have committed $6.2bn across 45 transactions
Funds managed by Pharmakon Advisors have committed $6.2bn across 45 transactions Historical Investment Performance as of January 2022 (Private Funds)1 Private Fund I II III IV V Launch Date June 2009 March 2011 February 2013 December 2015 June 2019 Founded in 2009; manager of the BioPharma Credit
BioPharma Credit — Investor Presentation (September 2022) on 6ix